BIO-DRIM
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation
| Coordinatore | CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 7˙978˙285 € |
| EC contributo | 5˙989˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | coordinator | 1˙344˙168.00 |
| 2 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 849˙660.00 |
| 3 |
Genome Identification Diagnostics GmbH
Organization address
address: Ebinger Str. 4 contact info |
DE (Strassberg) | participant | 611˙000.00 |
| 4 |
Nome Ente NON disponibile
Organization address
address: Videnska 1958/9 contact info |
CZ (PRAGUE 4) | participant | 500˙000.00 |
| 5 |
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Organization address
address: Allee de l'Ile Gloriette 5 contact info |
FR (NANTES) | participant | 500˙000.00 |
| 6 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 500˙000.00 |
| 7 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 294˙600.00 |
| 8 |
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Organization address
address: VIA FIORENTINA 151 contact info |
IT (SIENA) | participant | 229˙600.00 |
| 9 |
KLINIKUM DER UNIVERSITAET REGENSBURG
Organization address
address: FRANZ JOSEF STRAUSS ALLEE 11 contact info |
DE (REGENSBURG) | participant | 201˙600.00 |
| 10 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 201˙600.00 |
| 11 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 201˙340.00 |
| 12 |
CELLOGIC GMBH
Organization address
address: C/O CONGRESSA - ENGELDAMM 62 contact info |
DE (BERLIN) | participant | 199˙200.00 |
| 13 |
IMMUNOTECH SAS
Organization address
address: AVENUE JEAN DE LATTRE DE TASSIGNY 130 contact info |
FR (MARSEILLE) | participant | 114˙400.00 |
| 14 |
MILENIA BIOTEC GMBH
Organization address
address: VERSAILLER STRASSE 1 contact info |
DE (GIESSEN) | participant | 89˙832.00 |
| 15 |
ASTELLAS PHARMA EUROPE Ltd
Organization address
address: Lovett Road - Lovett House contact info |
UK (Staines) | participant | 76˙000.00 |
| 16 |
TEVA PHARMACEUTICALS EUROPE B.V.
Organization address
address: PIET HEINKADE 107 contact info |
NL (AMSTERDAM) | participant | 76˙000.00 |
| 17 |
BRISTOL-MYERS SQUIBB GMBH & CO. KGAA
Organization address
address: ARNULFSTRASSE 29 contact info |
DE (MUNICH) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. However, data were almost completely generated by “trial-and-error” observational studies. It suggests an unmet need to stratify transplant (Tx) patients regarding their immunological responsiveness to the allograft and their respective individual need of IS. The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as “operationally tolerant” by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings–Indices of Tolerance (IOT) and RISET but also of other international groups.'
Introduzione (Teaser)
Improving long-term outcome and decreasing the adverse effects associated with immunosuppression remains a significant clinical challenge. A European study proposes to tailor the immunosuppressive regimen to individual patient needs using biomarkers.